Proportions of patients achieving remission rate during induction therapy Up to 42 days [clinicaltrials_resource:a895dfdce3d5519710b57cad3fd129c0]
Patients receive treatment as in induction therapy, plus G-CSF SC beginning on day 16 and continuing until blood counts recover. If CSF is clear by day 10 of induction, patients receive cytarabine IT on days 0, 10, and 35. If CSF is not clear, patients receive triple intrathecal therapy (TIT; cytarabine, hydrocortisone, methotrexate) on days 0 and 10.
See Detailed Description
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Proportions of patients achieving remission rate during induction therapy Up to 42 days [clinicaltrials_resource:a895dfdce3d5519710b57cad3fd129c0]
Patients receive treatment as in induction therapy, plus G-CSF SC beginning on day 16 and continuing until blood counts recover. If CSF is clear by day 10 of induction, patients receive cytarabine IT on days 0, 10, and 35. If CSF is not clear, patients receive triple intrathecal therapy (TIT; cytarabine, hydrocortisone, methotrexate) on days 0 and 10.
See Detailed Description
Bio2RDF identifier
a895dfdce3d5519710b57cad3fd129c0
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:a895dfdce3d5519710b57cad3fd129c0
measure [clinicaltrials_vocabulary:measure]
Proportions of patients achieving remission rate during induction therapy
time frame [clinicaltrials_vocabulary:time-frame]
Up to 42 days
description
Patients receive treatment as ...... d 10.
See Detailed Description
identifier
clinicaltrials_resource:a895dfdce3d5519710b57cad3fd129c0
title
Proportions of patients achieving remission rate during induction therapy Up to 42 days
@en
type
label
Proportions of patients achiev ...... 5dfdce3d5519710b57cad3fd129c0]
@en